LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
43 hedge funds and large institutions have $97.7M invested in LogicBio Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 20 increasing their positions, 8 reducing their positions, and 2 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
77% more capital invested
Capital invested by funds: $55.2M → $97.7M (+$42.4M)
0% more funds holding
Funds holding: 43 → 43 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.32M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$755K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$262K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$218K |
| 5 |
State Street
Boston,
Massachusetts
|
+$203K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$759K |
| 2 |
JP Morgan Chase
New York
|
-$385K |
| 3 |
SC
Samlyn Capital
New York
|
-$76K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$58K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$9.67K |
LOGC Hedge Fund Activity: Q2 2020 in Review
43 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q2 2020, worth a combined $97.7M — up 77% from $55.2M a quarter earlier.
Fund positioning in LOGC was balanced in Q2 2020: 2 funds opened new positions, 2 closed out, 20 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $1.32M. The largest seller was Adage Capital Partners, cutting an estimated $759K.
- 43 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $97.7M of LogicBio Therapeutics, Inc. Common Stock stock for Q2 2020, up 77% quarter-over-quarter.
- 2 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q2 2020 and 2 closed out, a net change of 0 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $1.32M added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q2 2020 was Adage Capital Partners, an estimated $759K sold.
Based on aggregated 13F filings for Q2 2020.